Teva Pharmaceutical Industries Ltd. (TEVA)

7.95
0.20 2.50
NYSE : Health Technology
Prev Close 8.15
Open 8.33
Day Low/High 7.84 / 8.33
52 Wk Low/High 6.07 / 23.97
Volume 27.02M
Avg Volume 20.59M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 7.76B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Markets Finish Lower as Marco Rubio Now Opposes GOP Tax Bill

Markets Finish Lower as Marco Rubio Now Opposes GOP Tax Bill

The Dow Jones Industrial Average declined on Thursday after securing new records for four consecutive days.

Teva is Forming a Long-term Breakout Setup, as CEO Announces Layoffs

Teva is Forming a Long-term Breakout Setup, as CEO Announces Layoffs

Teva's price action has been a disaster so far this year, but that could be about to change. The long-term price action suggests traders are warming to Teva's turnaround plan.

Teva Options Jump to Record Amid New CEO's Latest Bid for Turnaround

Teva Options Jump to Record Amid New CEO's Latest Bid for Turnaround

Teva options now total more than Pfizer and Merck combined.

Allergan Is Trading Higher Today

But the stock is still undervalued, and we have our doubts about deal speculation.

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Stocks were slightly higher.

Dow Pushes to New Record High as Disney Buys Most of Fox

Dow Pushes to New Record High as Disney Buys Most of Fox

The Dow reaches a new intraday record high Thursday, following Walt Disney's deal to buy Twenty-First Century Fox's film and TV businesses for $52.4 billion.

Teva Announces Restructuring Plan And Additional Measures To Improve Its Business And Financial Performance

Teva Announces Restructuring Plan And Additional Measures To Improve Its Business And Financial Performance

Teva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) announced today a comprehensive restructuring plan to significantly reduce its cost base, unify and simplify its organization and improve business performance,...

Applied Materials, VMware, Kemet: 'Mad Money' Lightning Round

Applied Materials, VMware, Kemet: 'Mad Money' Lightning Round

Jim Cramer is bullish on Applied Materials, VMware, Kemet, Finisar.

The Fed and The Bull: Cramer's 'Mad Money' Recap (Wednesday 12/13/17)

The Fed and The Bull: Cramer's 'Mad Money' Recap (Wednesday 12/13/17)

Jim Cramer says he's optimistic this bull will stay strong, but it's always prudent to take gains and build a cash position.

Teva To Host Conference Call To Discuss Restructuring Plan And Additional Measures To Improve Its Business And Financial Performance At 8:00 A.m. ET On December 14, 2017

Teva To Host Conference Call To Discuss Restructuring Plan And Additional Measures To Improve Its Business And Financial Performance At 8:00 A.m. ET On December 14, 2017

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will issue a press release on its restructuring plan and additional measures to improve its business and financial performance on Thursday, December...

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

The broadcast scored an 11.6 metered rating, tops on the night, but short of last week's total.

Dow and S&P 500 Post New Records as Concerns Ebb Over New York Explosion

Dow and S&P 500 Post New Records as Concerns Ebb Over New York Explosion

The Dow, S&P 500 and Nasdaq all finished higher on Monday.

Teva Stock Rises After Announcing Launch of Generic Viagra Competitor

Teva Stock Rises After Announcing Launch of Generic Viagra Competitor

Viagra has annual sales of about $1.4 billion.

Teva Announces Exclusive Launch Of Generic Viagra® Tablets In The United States

Teva Announces Exclusive Launch Of Generic Viagra® Tablets In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of its generic Viagra ®1 (sildenafil citrate) tablets in the U.

Reiterating Our 'Don't Sell' Thesis on Allergan

We believe the impact of Revance's announcement will be overcome, but are downgrading the stock now to allow time for the headline dust to settle.

The New England Journal Of Medicine Publishes Data From Pivotal Phase III Trial Of Fremanezumab For The Preventive Treatment Of Chronic Migraine

The New England Journal Of Medicine Publishes Data From Pivotal Phase III Trial Of Fremanezumab For The Preventive Treatment Of Chronic Migraine

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose regimens of...

Teva Shares Close Higher as Company Vows to Unleash Detailed Restructuring Plan

Teva Shares Close Higher as Company Vows to Unleash Detailed Restructuring Plan

The Israel-based drugmaker on Nov. 27 unveiled a a new organizational structure and said it plans to announce a detailed restructuring plan next month.

(Graphic: Business Wire)

(Graphic: Business Wire)

Teva Pharmaceutical Industries Ltd. (NYSE & TASE:TEVA) announced today a new organization and leadership structure aimed to achieve better commercial focus and drive value creation.

Stocks Close Out Black Friday Trading at New Records as Retail, Energy Lead

Stocks Close Out Black Friday Trading at New Records as Retail, Energy Lead

As consumers across the U.S. kick off the busiest shopping season of the year, Wall Street finished the week in solidly positive territory with the S&P 500 and Nasdaq both closing at record highs.

Markets Close 'Green' on Black Friday

Markets Close 'Green' on Black Friday

While shoppers were busy looking for bargains at the mall, traders were busy doing the same on Wall Street.

Stocks Eye Weekly Gains as Nasdaq, S&P 500 Reach Records on Black Friday

Stocks Eye Weekly Gains as Nasdaq, S&P 500 Reach Records on Black Friday

As consumers across the U.S. kick off the busiest shopping season of the year, Wall Street continues higher on Friday.

S&P 500, Nasdaq Open to New Records as Wall Street Warms Up to Retail

S&P 500, Nasdaq Open to New Records as Wall Street Warms Up to Retail

As consumers across the U.S. kick off the busiest shopping season of the year, Wall Street opens higher on Friday.

Wall Street Poised for Gains as Retailers Gobble Up Strong Black Friday Sales

Wall Street Poised for Gains as Retailers Gobble Up Strong Black Friday Sales

As consumers across the U.S. kick off the busiest shopping season of the year, Wall Street is indicated to open higher on Friday.

Black Friday, Uber, Tesla, Teva - 5 Things You Must Know Before the Market Opens

Black Friday, Uber, Tesla, Teva - 5 Things You Must Know Before the Market Opens

U.S. stock futures are higher on Friday, as both retailers and shoppers prepare for the frenzy that is Black Friday.

Teva Spikes in Pre-Market Amid Reports of Significant U.S. Job Cuts

Teva Spikes in Pre-Market Amid Reports of Significant U.S. Job Cuts

Teva Pharmaceuticals, the world's biggest generic drugmaker, could be preparing major cuts to its 6,800-strong U.S. workforce amid slumping profits and falling prices.

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

The troubled drug firm slashed its dividend by 75% in August, but its current dividend payout ratio and yield can tell us a lot about the future.

Income Seeker: Teva Hard Pressed to Maintain its Dividend in the Long Term

Can Teva, which slashed its dividend by 75% in August, maintain its current quarterly dividend?

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Teva Announces Prescription Copay Savings Program For Generic Gleevec® Tablets In The United States

Teva Announces Prescription Copay Savings Program For Generic Gleevec® Tablets In The United States

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd.

Teva's Stock Could Crash Another 50% After Debt Cut to Junk

Teva's Stock Could Crash Another 50% After Debt Cut to Junk

Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.

TheStreet Quant Rating: D (Sell)